Hundreds of billions of eye drug market, a large number of pharmaceutical companies are making efforts.

Pharmaceutical Network Market Analysis: Recently, Polar Bio and Eyenovia announced the signing of a cooperation agreement.
Under the terms of the agreement, Eyenovia is expected to receive a total of up to $45.75 million, including the first payment and additional funding based on clinical development milestones, including the start-up and approval of Polar Creatures' registration in China and South Korea, as well as related research and development costs.
fact, this year is the second time this year with the United States ophthalmology enterprises.
announced in March that it had acquired the right to develop and commercialize XIPERE™, a core product of Clearside Biomedical, Inc., a U.S. biopharmaceutical company dedicated to the development and delivery of treatments for under-eye diseases, in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan).
fact, for the polar biology in the field of ophthalmology drugs recently, industry insiders believe that this is mainly due to the rapid growth of the ophthalmology drug market, resulting in a competition for companies.
In recent years, due to the aging of the population, the widespread use of electronic products, improper use of the eye and other lifestyle changes, so that the incidence of various types of eye diseases in China is on the rise, eye infections, conjunctivitis, macular degeneration, dry eye disease and other eye diseases increased significantly.
, china's ophthalmology market grew from 46.7 billion yuan to 86.6 billion yuan in 2013-2017, with a compound annual growth rate of 16.7%, according to data released last year.
With the increase in the incidence of ophthalmology, the upgrading of ophthalmology treatment technology and the improvement of patient awareness, the size of China's ophthalmology market is expected to continue to grow at a rate of about 14% between 2018 and 2022.
, the total size of the ophthalmology market is expected to exceed 100 billion yuan.
but contrary to the huge market size, there is a lack of therapeutic drugs in the field of ophthalmology in China.
, because the domestic ophthalmology companies started late, the foundation and technology accumulation want to be weak, but also make Tiantian Pharmaceuticals, Novarma Pharmaceuticals, Erkang and other foreign capital in the domestic market occupies the main market.
2018, according to the situation of ophthalmology in public hospitals in key provinces and cities in China, imported drugs accounted for 64.08 percent, while domestic drugs accounted for only 35.92 percent.
, with the improvement of people's awareness of eye protection and the continued growth of market size, domestic pharmaceutical companies in recent years began to scramble to lay out the field of ophthalmology.
As in November last year, Hengrui Pharmaceuticals announced that it had spent heavily to reach an agreement with Novoliq to introduce CyclASolTM (0.1% cyclosporine A preparation) and NOVO03 (perfluorohexyl octane), a drug used by Novoliq of Germany for the treatment of dry eye disease, and that Hengrui would be awarded the right to develop, produce and market the two products in China.
In June 2019, Conzer Pharmaceuticals, through its wholly-owned subsidiary, entered into a license agreement with Sun Pharmaceutical Industries Ltd., a global pharmaceutical company focused on branded innovative and complex generics, for its product 0.09% cyclosporine A eye drops, an innovative treatment for dry eye disease.
, on November 5th it was announced that it was working with SPARC to introduce three eye products, Xelpros, eye drops PDP-716 and SDN-037.
In April 2019, Xingqi eye drug olotatin eye drops were approved for production by the State Drug Administration, mainly used to treat the signs and symptoms of allergic conjunctivitis;
, the eye disease market is a growing market, and the future realization of import substitution will be the focus of the development of the ophthalmology industry.
.